Full name
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-2)
NCT Number
NCT05600777
Geography
US
Non-US
Locations
Australia, Czechia, Germany, India, Republic of Korea, New Zealand, Slovakia, Taiwan, United Kingdom, United States
Primary Endpoints
Change in 24-Hour Cough Frequency at Week 24
External Link
https://clinicaltrials.gov/study/NCT05600777
Order
2
Disease
Version
Phase
3
Status
Recruiting